Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells

Many breast cancer deaths result from tumors acquiring resistance to available therapies. Thus, new therapeutic agents are needed for targeting drug-resistant breast cancers. Drug-refractory breast cancers include HER2+ tumors that have acquired resistance to HER2-targeted antibodies and kinase inhi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Ferreira, Renan B., Wang, Mengxiong, Law, Mary E., Davis, Bradley J., Bartley, Ashton N., Higgins, Paul J., Kilberg, Michael S., Santostefano, Katherine E., Terada, Naohiro, Heldermon, Coy D., Castellano, Ronald K., Law, Brian K.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5438706/
https://ncbi.nlm.nih.gov/pubmed/28423644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15952
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados